These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 22265055)

  • 1. Assessment of pharmacoeconomic evaluations submitted for reimbursement in Korea.
    Yim EY; Lim SH; Oh MJ; Park HK; Gong JR; Park SE; Yi SY
    Value Health; 2012; 15(1 Suppl):S104-10. PubMed ID: 22265055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation on the first 2 years of the positive list system in South Korea.
    Park SE; Lim SH; Choi HW; Lee SM; Kim DW; Yim EY; Kim KH; Yi SY
    Health Policy; 2012 Jan; 104(1):32-9. PubMed ID: 22001369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using pharmacoeconomic analysis to make drug insurance coverage decisions.
    Anis AH; Rahman T; Schechter MT
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 2):119-26. PubMed ID: 10176146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug reimbursement decision-making in Thailand, China, and South Korea.
    Ngorsuraches S; Meng W; Kim BY; Kulsomboon V
    Value Health; 2012; 15(1 Suppl):S120-5. PubMed ID: 22265058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
    Hoomans T; van der Roer N; Severens JL; Delwel GO
    Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests.
    Cleemput I; van Wilder P; Huybrechts M; Vrijens F
    Value Health; 2009 Jun; 12(4):441-9. PubMed ID: 19900251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of economic evidence in coverage decision-making in South Korea.
    Bae EY; Kim HJ; Lee HJ; Jang J; Lee SM; Jung Y; Yoon N; Kim TK; Kim K; Yang BM
    PLoS One; 2018; 13(10):e0206121. PubMed ID: 30356251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using economic evaluations to make formulary coverage decisions. So much for guidelines.
    Anis AH; Gagnon Y
    Pharmacoeconomics; 2000 Jul; 18(1):55-62. PubMed ID: 11010604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacoeconomic guidelines and their implementation in the positive list system in South Korea.
    Bae EY; Lee EK
    Value Health; 2009; 12 Suppl 3():S36-41. PubMed ID: 20586979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methodological quality of economic evaluations of new pharmaceuticals in The Netherlands.
    Hoomans T; Severens JL; van der Roer N; Delwel GO
    Pharmacoeconomics; 2012 Mar; 30(3):219-27. PubMed ID: 22074610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eight-year experience of using HTA in drug reimbursement: South Korea.
    Bae EY; Hong JM; Kwon HY; Jang S; Lee HJ; Bae S; Yang BM
    Health Policy; 2016 Jun; 120(6):612-20. PubMed ID: 27086557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different policy outcomes of the new drugs and currently listed drugs under the positive list system in South Korea.
    Lee EK; Kim BY; Lim JY; Park MH
    Value Health; 2012; 15(1 Suppl):S100-3. PubMed ID: 22265054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evaluation and use of economic evidence to inform cancer drug reimbursement decisions in Canada.
    Yong JH; Beca J; Hoch JS
    Pharmacoeconomics; 2013 Mar; 31(3):229-36. PubMed ID: 23322588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Pharmacoeconomic Evaluation Process in Ireland.
    McCullagh L; Barry M
    Pharmacoeconomics; 2016 Dec; 34(12):1267-1276. PubMed ID: 27473640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea.
    Kim ES; Kim JA; Lee EK
    Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):401-409. PubMed ID: 28010146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unravelling drug reimbursement outcomes: a comparative study of the role of pharmacoeconomic evidence in Dutch and Swedish reimbursement decision making.
    Franken M; Nilsson F; Sandmann F; de Boer A; Koopmanschap M
    Pharmacoeconomics; 2013 Sep; 31(9):781-97. PubMed ID: 23839699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond.
    Rocchi A; Menon D; Verma S; Miller E
    Value Health; 2008; 11(4):771-83. PubMed ID: 18179658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoeconomic evaluation in Ireland: a review of the process.
    Tilson L; O'Leary A; Usher C; Barry M
    Pharmacoeconomics; 2010; 28(4):307-22. PubMed ID: 20222754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.
    Vegter S; Rozenbaum MH; Postema R; Tolley K; Postma MJ
    Clin Ther; 2010 Aug; 32(9):1651-61. PubMed ID: 20974323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.